FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM
Abbott Diabetes Care, Inc. · Decision date Sep 23, 2016
What did the FDA approve?
FDA approved PMA P150021 on September 23, 2016, for the FreeStyle Libre Pro Flash Glucose Monitoring System from Abbott Diabetes Care, Inc. The approval covers a professional continuous glucose monitoring device for detecting trends and tracking patterns in adults 18 and older with diabetes. The system is intended for health care professionals, requires a prescription, and does not require user calibration with blood glucose values.
Sensor readings are made available to patients only through consultation with a health care professional. The statement describes the system as aiding detection of glucose excursions above or below the desired range to support therapy adjustments, with interpretation based on trends and patterns over time using available reports. The source does not include independent proof of safety or clinical effectiveness beyond this stated purpose.
FDA approval order statement
The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The System is intended for use by health care professionals and requires a prescription. Readings from the FreeStyle Libre Pro Sensor are only made available to patients through consultation with a health care professional. The System does not require user calibration with blood glucose values.The FreeStyle Libre Pro System aids in the detection of glucose level excursions above or below the desired range, facilitating therapy adjustments. Interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should be based on the trends and patterns analyzed through time using the reports available.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 23, 2016
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150021
- Regulatory pathway
- Premarket approval application
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- MDS
- Decision code
- APPR
- Decision date
- Sep 23, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sensor, glucose, invasive.
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- MDS
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150021 received
Application receipt date recorded by FDA.
P150021 · FDA decision
APPR
P150021/S061 · Related supplement
Freestyle Libre Pro Flash Glucose Monitoring System
Timeline entries are records held by MedtechLedger for P150021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Diabetes Care, Inc. | PMA supplement | Sep 1, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Diabetes Care, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1360 S. Loop Rd., Alameda, CA, 94502
Sources and methodology
- Original FDA record: P150021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records